DYADIC INTERNATIONAL
1.1100
07-11月-24 13:09:45
15 分の遅延
株式
+0.0500
+4.72%
本日の幅
1.0400 - 1.1500
ISIN
N/A
ソース
NASDAQ
-
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
07 2 2022 08:30:01 提供 Nasdaq GlobeNewswire
-
20 1 2022 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
22 12 2021 09:12:47 提供 Nasdaq GlobeNewswire
-
17 12 2021 07:00:00 提供 Nasdaq GlobeNewswire
-
Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
10 11 2021 16:00:00 提供 Nasdaq GlobeNewswire
-
Dyadic Appoints Chief Business Officer to Executive Leadership Team
09 11 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
27 10 2021 16:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
10 9 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
28 6 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic announces development of COVID-19 Vaccine in India
26 5 2021 08:30:01 提供 Nasdaq GlobeNewswire
-
Dyadic to Present at Upcoming Events
03 5 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
22 4 2021 08:30:01 提供 Nasdaq GlobeNewswire
-
29 3 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
23 3 2021 09:00:01 提供 Nasdaq GlobeNewswire
-
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22 3 2021 21:00:00 提供 Nasdaq GlobeNewswire
-
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
22 3 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
18 3 2021 08:30:00 提供 Nasdaq GlobeNewswire
-
Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting
09 3 2021 08:30:00 提供 Nasdaq GlobeNewswire